Orbimed Advisors LLC Buys 10,000 Shares of Ascendis Pharma A/S $ASND

Orbimed Advisors LLC raised its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 5.8% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 181,977 shares of the biotechnology company’s stock after acquiring an additional 10,000 shares during the quarter. Orbimed Advisors LLC’s holdings in Ascendis Pharma A/S were worth $41,624,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ASND. Nomura Asset Management Co. Ltd. boosted its holdings in shares of Ascendis Pharma A/S by 57.5% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 43,701 shares of the biotechnology company’s stock valued at $9,319,000 after buying an additional 15,950 shares in the last quarter. Candriam S.C.A. increased its stake in shares of Ascendis Pharma A/S by 23.2% in the 1st quarter. Candriam S.C.A. now owns 230,278 shares of the biotechnology company’s stock worth $52,671,000 after acquiring an additional 43,338 shares in the last quarter. Braun Stacey Associates Inc. lifted its position in Ascendis Pharma A/S by 26.8% during the 4th quarter. Braun Stacey Associates Inc. now owns 119,095 shares of the biotechnology company’s stock valued at $25,396,000 after acquiring an additional 25,148 shares during the period. UBS Group AG boosted its stake in Ascendis Pharma A/S by 57.9% during the fourth quarter. UBS Group AG now owns 308,190 shares of the biotechnology company’s stock worth $65,718,000 after acquiring an additional 112,986 shares in the last quarter. Finally, Morse Asset Management Inc bought a new stake in Ascendis Pharma A/S during the fourth quarter worth about $1,384,000.

Insider Buying and Selling at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, insider Flemming Steen Jensen sold 19,460 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $238.49, for a total transaction of $4,641,015.40. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Jean Jacques Bienaime bought 400 shares of Ascendis Pharma A/S stock in a transaction on Tuesday, May 26th. The stock was acquired at an average cost of $237.80 per share, with a total value of $95,120.00. Following the acquisition, the director owned 400 shares in the company, valued at approximately $95,120. This represents a ? increase in their position. The SEC filing for this purchase provides additional information. Company insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ ASND opened at $253.86 on Monday. The firm’s 50 day moving average price is $244.08 and its 200-day moving average price is $233.59. Ascendis Pharma A/S has a 52-week low of $160.86 and a 52-week high of $282.15. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The company has a market cap of $15.84 billion, a PE ratio of 29.28 and a beta of 0.37.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to the consensus estimate of $362.47 million. On average, equities research analysts expect that Ascendis Pharma A/S will post 4.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Wall Street Zen downgraded shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Royal Bank Of Canada boosted their price target on Ascendis Pharma A/S from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Evercore restated an “outperform” rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Weiss Ratings raised Ascendis Pharma A/S from a “sell (d)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. Finally, Wedbush reiterated an “outperform” rating and set a $273.00 price objective on shares of Ascendis Pharma A/S in a research note on Thursday, April 9th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Buy” and an average target price of $296.72.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.